Jeffrey Zhong, MD, discusses the effect of upfront enfortumab vedotin/pembrolizumab dose reduction on treatment efficacy in advanced urothelial carcinoma.
Jeffrey Zhong, MD
Advertisement
Jeffrey Zhong, MD, is a hematology/oncology fellow at Case Western Reserve University.
Articles by Jeffrey Zhong, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5